$QTRX

DONNELLY WILLIAM P purchased $286K of QTRX (indirect holdings)

DONNELLY WILLIAM P purchased 99,400 indirectly-held shares of Quanterix Corp (QTRX) at an average of $2.88 ($2.75–$2.93, $0.29M total) across 2 trades over 2026-08-12 to 2026-08-13.

Original reporting
SEC EDGAR · DONNELLY WILLIAM P
Published Aug 14, 2026, 8:01 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 14, 2026, 8:46 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$QTRX
Bullish
low confidence
Mentioned
$QTRX
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$QTRXBullishLow
01

Why it matters

The newest fact is the director’s indirect open-market purchase of 99,400 shares across two trades at specified prices, filed on 2026-08-14.

02

Market read

This provides a fresh insider-buy datapoint for QTRX, but it is unlikely to be a standalone driver of price without accompanying company-specific catalysts.

03

What to watch

The filing does not state the rationale, whether the shares were acquired through a trust, or whether there are concurrent sales; traders may want to check for other recent Form 4 activity around the same period.

Relevance 5/10Novelty 4/10Timing: Filed 2026-08-14, covering purchases executed 2026-08-12 to 2026-08-13.

Background

The article is an SEC Form 4 insider transaction disclosure for Quanterix (QTRX).

Company-level read

Ticker impact

$QTRXBullishLow confidence
Context

Quanterix disclosed a director’s indirect open-market purchase of 99,400 shares at $2.7500 to $2.9300 (weighted avg $2.8808).

Expected impact

Likely limited near-term impact; any effect should be small and fade unless followed by additional disclosures or company-specific news.

Evidence & confidence

Form 4 insider buys can be informative, but this filing provides no new operational, financial, or regulatory information, and the transaction size is moderate relative to typical market-moving events.

Market effects

No direct sector read-through; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Indirect holdings and lack of a 10b5-1 plan detail can reduce interpretability; the buy may reflect diversification or pre-existing arrangements rather than a new conviction.

Key entities

  • Quanterix Corp

    Subject of the Form 4 insider transaction disclosure.

  • Donnelly William P

    Director who reported an indirect open-market purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$QTRXHighAI 9/10

Quanterix (QTRX) Q2 2026 Earnings Call Transcript

Quanterix (QTRX) said Q2 2026 revenue was about $3 million (9%) below May guidance, citing broad-based shortfalls and commercial execution challenges. The company lowered 2026 revenue guidance to $142 million to $148 million from $169 million to $174 million and expects ~$80 million cash by year-end. Quanterix added commercial leaders (Jim Gute, Geoff Albrecht) and reorganized sales, citing Akoya integration savings of $85 million annually.

$QTRXMed

Quanterix Reshapes Sales Strategy, Targets Q4 FDA Decision for Alzheimer’s Blood Test

Quanterix (QTRX) said it completed Akoya Biosciences integration in Q2 and delivered $85M in revenue synergies. It is reshaping sales teams and expects clinical-trial bookings to rise QoQ. For its LucentAD Complete Alzheimer’s blood test, Quanterix filed a 510(k) in January and targets an FDA decision in Q4, possibly into Q1, citing a CMS price crosswalk of $897. It targets $10M diagnostics revenue in 2026.

$QTRXMed

Quanterix Q2 Earnings Call Highlights

Quanterix (NASDAQ:QTRX) reported Q2 cash use of $5.7M and cash of $96.9M. Simoa revenue was $20.6M, Spatial $12.3M, and GAAP gross margin 38.5%. Management guided Q3 revenue flat to slightly above Q2 and cited Akoya integration, $85M annualized savings, and commercial reorganization. FDA timing for LucentAD Complete is targeted for late 2026.

$QTRXHigh

Quanterix Corp (QTRX): Results of Operations and Financial Condition

Quanterix Corp (QTRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Quanterix Releases Financial Results for the Second Quarter of 2026 Reports $32.9 million in revenue and $96.9 million of cash and marketable securities Company accelerating initiatives to drive commercial effectiveness Revises financial outlook for 2026 and extends

$TTRXMedAI 8/10

Top Biotech Gainers: TTRX Turns Heads, LIXT Shifts To AI Energy, CNXU Update, QTRX, TRAX On Watch

Turn Therapeutics (TTRX) rose over 20% after interim Phase 2 results for GX-03 in atopic dermatitis, with 92.6% achieving EASI-50 at 4 weeks. Conexeu (CNXU) gained ~19% on preclinical B.R.E.A.S.T. bioprinting progress. Rallybio (RLYB) jumped on plans to acquire Avenzo via a $215M investment. LIXTE (LIXT) surged on an AI energy pivot; Quanterix (QTRX) rose on insider SEC filing.